NCT06369064 Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient
| NCT ID | NCT06369064 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nīmes |
| Condition | Acute Kidney Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-07-03 |
| Primary Completion | 2028-08-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-07-03 with a primary completion date of 2028-08-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In patients requiring renal replacement therapy (RRT) in the intensive care unit (ICU), continuous techniques are predominantly using due to better hemodynamic tolerance. The most employed techniques in ICU are continuous venovenous hemodiafiltration (CVVHDF) and continuous venovenous hemodialysis (CVVHD). To our knowledge, there are no prospective studies comparing the efficiency of these two techniques with the same dose of dialysis (and the same filter). In the CompEER study, we aim to compare the efficiency of CVVHD and CVVHDF on urea reduction rate in intensive care patients with acute kidney injury. The research hypothesis is that CVVHD citrate technique is as effective as CVVHDF heparin technique for urea reduction and provides prolonged and stable clearance, facilitating antibiotic management during RRT.
Eligibility Criteria
Inclusion criteria: * Adult patients hospitalized in ICU * Undergo RRT session because of AKI stage 3 * At least one among criteria: pH \< 7,20 / Blood urea \> 30mM / Fluid overload uncontrolled by with PaCO₂ \< 35 mmHg or mixed acidosis with PaCO₂ \< 50 mmHg. * Oliguria lasting 72 hours or longer * Patients undergoing their first session of extracorporeal blood purification, initiated less than 12 hours prior to randomization * Patient having given free and informed consent, and having signed the consent form or patient included in an emergency situation * Patient affiliated with Social Security. Exclusion criteria: * End-stage chronic kidney disease on dialysis * Intoxication with a dialyzable toxin (lithium * Criteria for emergency dialysis initiation: hyperkaliemia \>6,5mM with electrocardiographic signs * Medical contraindication to regional citrate: severe liver failure * Medical contraindication to anticoagulation or heparin anticoagulation: heparin induced thrombopenia or uncontrolled bleeding * Pregnant women, parturient or breast-feeding patient
Contact & Investigator
Claire Roger
PRINCIPAL INVESTIGATOR
CHU Nimes
Frequently Asked Questions
Who can join the NCT06369064 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06369064 currently recruiting?
Yes, NCT06369064 is actively recruiting participants. Contact the research team at Claire.roger@chu-nimes.fr for enrollment information.
Where is the NCT06369064 trial being conducted?
This trial is being conducted at Nîmes, France.
Who is sponsoring the NCT06369064 clinical trial?
NCT06369064 is sponsored by Centre Hospitalier Universitaire de Nīmes. The principal investigator is Claire Roger at CHU Nimes. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.